MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c)
MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome that acts as a signaling molecule between mitochondria and the nucleus. Discovered in 2015 by Dr. Changhan David Lee at USC, MOTS-c activates AMPK (the same pathway triggered by exercise and metformin) and improves glucose metabolism, insulin sensitivity, and fatty acid oxidation. It is sometimes referred to as an exercise mimetic because it produces metabolic effects similar to physical activity.
FormBlends Peptide Context
Reviewed May 14, 2026Treat Mots C peptide guide as context for a safer next conversation. It should help with frame benefits, dosing, evidence strength, sourcing, and safety boundaries in one place, while keeping the reader focused on peptide therapy, evidence limits, provider oversight, and the difference between general information and personal medical advice.
- Confirm whether the page is discussing approved care, compounded access, off-label use, or research-only context.
- Check the date, evidence quality, safety limits, and whether newer clinical or regulatory updates may change the answer.
- Ask a licensed clinician how the information applies to your history, medications, labs, goals, and risk profile.
Clinical decision snapshot
MOTS-c authority snapshot
MOTS-c is evaluated by mechanism, evidence quality, regulatory status, practical access, and safety questions a licensed clinician would need to review before use.
Evidence signal
Early clinical or translational evidence
Regulatory reality
Not specifically addressed in 2023/2026 regulatory actions
Safety screen
Injection site reactions, Mild hypoglycemia if combined with other glucose-lowering agents, Mild gastrointestinal discomfort should be reviewed in context.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
Decision path
What is the supervised-review path for MOTS-c?
MOTS-c should be evaluated by evidence quality, safety status, source quality, dosing context, and whether the goal fits a legitimate clinical pathway. This page is a research and decision aid, not a self-prescribing guide.
- Peptide
- MOTS-c
- Category
- Metabolic
- Evidence
- Early clinical or translational evidence
- FDA status
- Not FDA approved
Step 1
Check evidence level
MOTS-c is a mitochondrial-derived peptide discovered in 2015 by Dr. Changhan Lee at USC. The science is promising but young. Most data comes from animal models and cell culture. One small human observational study linked MOTS-c levels to exercise capacity and metabolic health. No human interventional trials have been completed yet.
Review evidenceStep 2
Screen safety context
Injection site reactions, Mild hypoglycemia if combined with other glucose-lowering agents, Mild gastrointestinal discomfort should be discussed in light of history, dose, and source.
Check side effectsStep 3
Confirm access route
If FormBlends offers access, review the product page and provider pathway before deciding.
Review product accessLast updated: April 3, 2026
Typical Dosage
5-10 mg injected subcutaneously, 3-5 times per week. Protocols typically run for 4-8 week cycles.
Administration
Subcutaneous injection
Typical Cost
$150-350/month
FDA Status
Not FDA Approved
Half-Life
Not well-characterized in humans. Animal data suggests rapid clearance.
Onset of Action
Animal studies show metabolic improvements within 1-2 weeks of daily dosing. Human onset data doesn't exist yet.
Bioavailability
Subcutaneous injection is standard. No oral bioavailability data.
About MOTS-c
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide encoded by the mitochondrial genome, not the nuclear genome. It was discovered in 2015 by Dr. Changhan Lee's lab at the University of Southern California. Molecular weight: approximately 2,174 Da.
The discovery of MOTS-c was significant because it showed that mitochondria don't just generate energy. They also produce signaling molecules that regulate metabolism throughout the entire body. MOTS-c is released from mitochondria into the bloodstream, travels to distant tissues (particularly skeletal muscle), and activates metabolic pathways there. This is called retrograde signaling, and it changed how researchers think about mitochondrial function.
The original 2015 paper in Cell Metabolism (PMID: 25738459) showed that MOTS-c activates AMPK (a master metabolic switch), enhances glucose uptake in muscle, and prevents insulin resistance in mice fed a high-fat diet. Aged mice treated with MOTS-c showed improvements in metabolic function that made them look metabolically younger.
A 2021 follow-up in Nature Communications (PMID: 33446657) added an important human observation: MOTS-c levels in blood increase during exercise. The study also showed that injecting MOTS-c into old mice improved their physical capacity and muscle homeostasis. The researchers proposed that MOTS-c might be one of the molecular signals that mediates the health benefits of exercise.
That said, no human interventional trial has been completed for MOTS-c as of April 2026. Everything we know about its therapeutic potential comes from mouse studies and human observational data. The compound is still in the early stages of translation from bench to bedside.
Practitioners who prescribe MOTS-c typically use doses of 5-10 mg injected subcutaneously 2-3 times per week. These doses are extrapolated from the animal studies, adjusted for body weight. There's no human dose-response data to guide prescribing, which is an honest limitation.
MOTS-c is part of a broader class called mitochondrial-derived peptides (MDPs) that also includes humanin and SHLP peptides. Researchers at USC and other institutions are actively investigating whether declining MDP levels contribute to age-related metabolic disease and whether supplementation can reverse that decline.
Store lyophilized MOTS-c at -20C. Reconstitute with bacteriostatic water, swirling gently. Use within 21 days when stored at 2-8C.
How MOTS-c Works
MOTS-c translocates to the cell nucleus under metabolic stress, where it regulates gene expression related to glucose metabolism and cellular stress responses. It activates AMPK (AMP-activated protein kinase), the master cellular energy sensor, which increases glucose uptake, enhances fatty acid oxidation, and improves mitochondrial function. MOTS-c also inhibits the folate-methionine cycle, which shifts cellular metabolism toward a more efficient state and reduces the accumulation of metabolic byproducts.
Receptor targets:
Benefits
- Activates AMPK pathway similarly to exercise
- Improves insulin sensitivity and glucose metabolism
- Promotes fat oxidation and supports weight management
- Enhances mitochondrial function and energy production
- May protect against age-related metabolic decline
- Reduces inflammation associated with metabolic dysfunction
What Does the Research Say?
MOTS-c is a mitochondrial-derived peptide discovered in 2015 by Dr. Changhan Lee at USC. The science is promising but young. Most data comes from animal models and cell culture. One small human observational study linked MOTS-c levels to exercise capacity and metabolic health. No human interventional trials have been completed yet.
The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity
Cell Metabolism, 2015 · DOI · PubMed
Discovery paper showing MOTS-c targets skeletal muscle, activates AMPK, and prevents age-dependent and high-fat-diet-induced insulin resistance in mice
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
Nature Communications, 2021 · DOI · PubMed
Showed MOTS-c levels increase during exercise in humans, and MOTS-c treatment improved physical capacity and reversed age-related metabolic decline in old mice
PubMed evidence trail
Research sources used to frame this page
For MOTS-c, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Potential Side Effects
- Injection site reactions
- Mild hypoglycemia if combined with other glucose-lowering agents
- Mild gastrointestinal discomfort
- Fatigue during initial use
Drug Interactions
| Compound | Interaction | Severity |
|---|---|---|
| Metformin | Both MOTS-c and metformin activate AMPK. Using both together could produce additive metabolic effects, but this hasn't been studied. Monitor blood glucose if combining. | moderate |
Who Is MOTS-c For?
Women
No sex-specific human data. The 2021 Nature Communications study found MOTS-c levels increase during exercise equally in men and women.
Adults Over 50
Potentially the most relevant population. MOTS-c levels decline with age, and mouse studies show the most noticeable benefits in aged animals. But without human trials, this remains theoretical.
Athletes
Not currently on WADA's prohibited list. The exercise-MOTS-c connection (it increases naturally during exercise) makes it an interesting compound for exercise science research.
Regulatory Status
FDA Approved
No
Compounding Legal
Yes
2026 HHS Status
Not specifically addressed in 2023/2026 regulatory actions
MOTS-c is a newer compound that wasn't specifically named in the 2023 FDA peptide restrictions. Its compounding status has been largely unaffected.
Last verified: 2026-04-06
Stacking Options
MOTS-c is commonly stacked with the following peptides for enhanced results:
Conditions Addressed
Get MOTS-c from FormBlends
Pharmaceutical-grade mots-c with free physician consultation.
View Product DetailsFind a MOTS-c Clinic Near You
Browse peptide therapy clinics in your area that offer mots-c treatments.
Find Peptide Clinics